<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1979</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2026-22-1-137-148</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Trends and hotspots in genetic and therapeutic research on kidney renal clear cell carcinoma: a comprehensive bibliometric study</article-title><trans-title-group xml:lang="ru"><trans-title>Тренды и популярные направления в генетических и терапевтических исследованиях светлоклеточного почечно-клеточного рака: детальное библиометрическое исследование</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Amukti</surname><given-names>Danang Prasetyaning</given-names></name><address><country country="ID">Indonesia</country></address><bio><p>Department of Pharmacy, Faculty of Health Science</p></bio><email>danangpa@almaata.ac.id</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kusumawardani</surname><given-names>Nurul</given-names></name><address><country country="ID">Indonesia</country></address><bio><p>Department of Pharmacy, Faculty of Health Science</p></bio><email>danangpa@almaata.ac.id</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Estiningsih</surname><given-names>Daru</given-names></name><address><country country="ID">Indonesia</country></address><bio><p>Department of Pharmacy, Faculty of Health Science</p></bio><email>danangpa@almaata.ac.id</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Emelda</surname><given-names>Emelda</given-names></name><address><country country="ID">Indonesia</country></address><bio><p>Department of Pharmacy, Faculty of Health Science</p></bio><email>danangpa@almaata.ac.id</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Bachri</surname><given-names>Moch Saiful</given-names></name><address><country country="ID">Indonesia</country></address><bio><p>Faculty of Pharmacy</p></bio><email>danangpa@almaata.ac.id</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Pratami</surname><given-names>Ria Indah</given-names></name><address><country country="ID">Indonesia</country></address><bio><p>Faculty of Pharmacy</p></bio><email>danangpa@almaata.ac.id</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff id="aff1"><institution>Alma Ata University</institution></aff><aff id="aff2"><institution>Ahmad Dahlan University</institution></aff><pub-date date-type="pub" iso-8601-date="2026-07-10" publication-format="electronic"><day>10</day><month>07</month><year>2026</year></pub-date><volume>22</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>137</fpage><lpage>148</lpage><history><date date-type="received" iso-8601-date="2025-10-08"><day>08</day><month>10</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2026-04-28"><day>28</day><month>04</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, АБВ-пресс</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1979">https://oncourology.abvpress.ru/oncur/article/view/1979</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Kidney renal clear cell carcinoma (KIRC) is the most common subtype of kidney cancer, making up about 70–80 % of all cases. This cancer displays high molecular heterogeneity and responds poorly to standard therapies. Over the past decade, research on KIRC has shifted significantly toward genetically based treatments and precision medicine.</p> <p><bold>Aim.</bold> To analyze global trends in KIRC genetics and treatment research through a bibliometric review of the Scopus database from 2009 to 2025.</p> <p><bold>Materials and methods.</bold> The method involved collecting documents with the keyword “Kidney Renal Clear Cell Carcinoma” in English. The data were analyzed using VOSviewer software for keyword network visualization and Bibliometrix (R Studio) for descriptive analysis, including publication growth, international collaborations, affiliations, and citations. Analysis was also conducted on thematic clustering and the identification of the most influential authors and institutions.</p> <p><bold>Results. </bold>There were 870 publications across 285 sources, with an annual growth rate of 28.31 %. International collaborations made up only 9.66 %, highlighting the dominance of domestic partnerships. The most active author was Wang Y, with 58 publications and 773 citations. Three main thematic groups were identified: gene-based prognostic models, pan-cancer approaches, and molecular mechanisms of tumors. Topics like immunotherapy, multi-omics, and artificial intelligence experienced notable increases in citations<bold>.</bold></p> <p><bold>Conclusion.</bold> KIRC global research advanced quickly toward integrating genetically based precision therapies. This study provided a strategic foundation for research planning, funding, and international collaboration in molecular oncology.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Светлоклеточный почечно-клеточный рак (скПКР) является наиболее распространенным типом рака почки и составляет 70–80 % всех случаев. Данное новообразование характеризуется высокой молекулярной гетерогенностью и плохо отвечает на стандартные методы терапии. За последнее десятилетие исследования скПКР существенно сместились в сторону генетически обоснованных методов лечения и персонализированной медицины.</p> <p><bold>Цель исследования</bold> – провести анализ глобальных тенденций в исследованиях генетики и лечения скПКР с помощью библиометрического обзора базы данных Scopus за период с 2009 по 2025 г.</p> <p><bold>Материалы и методы.</bold> Был проведен поиск публикаций по ключевой фразе “Kidney Renal Clear Cell Carcinoma” на английском языке. Данные анализировали с использованием программного обеспечения VOSviewer для визуализации сетей ключевых слов и Bibliometrix (R Studio) для описательного анализа, включая рост числа публикаций, международное сотрудничество, аффилиации и цитируемость. Также были проведены анализ тематической кластеризации и идентификация наиболее влиятельных авторов и учреждений.</p> <p><bold>Результаты.</bold> Было найдено 870 публикаций в 285 источниках, при этом каждый год количество публикаций увеличивалось в среднем на 28,31 %. Международные коллаборации составили лишь 9,66 %, что подчеркивает преобладание сотрудничества внутри стран. Наиболее активным автором был Y. Wang, имеющий 58 публикаций и 773 цитирования. Были выделены 3 основные тематические группы: прогностические модели на основе генов, панраковые подходы и молекулярные механизмы развития опухолей. Такие темы, как иммунотерапия, мультиомика и искусственный интеллект, продемонстрировали заметный рост цитируемости.</p> <p><bold>Заключение. </bold>Глобальные исследования скПКР быстро движутся в направлении интеграции генетически обоснованных персонализированных терапевтических подходов. Данная работа обеспечивает стратегическую основу для планирования исследований, финансирования и международного сотрудничества в области молекулярной онкологии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>kidney renal clear cell carcinoma</kwd><kwd>bibliometric analysis</kwd><kwd>precision oncology</kwd><kwd>genetic biomarkers</kwd><kwd>multi-omics integration</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>светлоклеточный почечно-клеточный рак</kwd><kwd>библиометрический анализ</kwd><kwd>прецизионная онкология</kwd><kwd>генетические биомаркеры</kwd><kwd>интеграция мультиомики</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ren H., Chen X., Ji M. et al. CRYAB is upregulated and predicts clinical prognosis in kidney renal clear cell carcinoma. IUBMB Life 2025;77(1):e2938. DOI: 10.1002/iub.2938</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zhang J., Zou B., Geng Y. et al. TRIM36 serves as a prognostic indicator linked to immune infiltration in KIRC. Heliyon 2025;11(4):e42540. DOI: 10.1016/j.heliyon.2025.e42540</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Jia C., Wang T., Cui D. et al. A metagene-based similarity network fusion approach for multi-omics data integration identified novel subtypes in renal cell carcinoma. Brief Bioinform 2024;25(6):bbae606. DOI: 10.1093/bib/bbae606</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kim I.H., Lee H.J. The frontline immunotherapy-based treatment of advanced clear cell renal cell carcinoma: current evidence and clinical perspective. Biomedicines 2022;10(2):251. DOI: 10.3390/biomedicines10020251</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Wang J., Chang H., Su M. et al. Identification of HGD and GSTZ1 as biomarkers involved metabolic reprogramming in kidney renal clear cell carcinoma. Int J Mol Sci 2022;23(9):4583. DOI: 10.3390/ijms23094583</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Xu K., Li D., Ji K. et al. Disulfidptosis-associated LncRNA signature predicts prognosis and immune response in kidney renal clear cell carcinoma. Biol Direct 2024;19(1):71. DOI: 10.1186/s13062-024-00517-7</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Li C., Zhang W., Fang T. et al. Identification of the Prognostic value among suppressor of cytokine signaling family members in kidney renal clear cell carcinoma. Front Mol Biosci 2021;8:585000. DOI: 10.3389/fmolb.2021.585000</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mehdi A., Riazalhosseini Y. Epigenome aberrations: emerging driving factors of the clear cell renal cell carcinoma. Int J Mol Sci 2017;18(8):1774. DOI: 10.3390/ijms18081774</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Heyliger S.O., Soliman K.F.A., Saulsbury M.D., Reams R.R. The identification of zinc-finger protein 433 as a possible prognostic biomarker for clear-cell renal cell carcinoma. Biomolecules 2021;11(8):1193. DOI: 10.3390/biom11081193</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zhang Z., Chen H., Yan D. et al. Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade. Oncogenesis 2023;12(1):37. DOI: 10.1038/s41389-023-00482-2</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ye Z., Zeng D., Zhou R. et al. Tumor microenvironment evaluation for gastrointestinal cancer in the era of immunotherapy and machine learning. Front Immunol 2022;13:819807. DOI: 10.3389/fimmu. 2022.819807</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Xia Q.D., Li B., Sun J.X. et al. Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma. Front Oncol 2023;13:1096341. DOI: 10.3389/fonc.2023.1096341</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chen M., Gao Y., Cao H. et al. Comprehensive analysis reveals dual biological function roles of EpCAM in kidney renal clear cell carcinoma. Heliyon 2023;10(1):e23505. DOI: 10.1016/j.heliyon.2023.e23505</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Chen Z., Chen C., Li L. et al. The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer. Comput Struct Biotechnol J 2021;19:5428–42. DOI: 10.1016/j.csbj.2021.09.029</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Amukti D.P., Irham L.M., Surono S. et al. Atherosclerosis research in the genomic era: global trends from 1983 to 2024. Bulgarian Cardiology [Internet] 2024;30(4):40–8. Available at: https://journal.bgcardio.org/article/143367/</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Irham L.M., Amukti D.P., Adikusuma W. et al. Applied bioinformatics in drug discovery and drug development: Bioinformatic analysis 1996–2024. Eds.: S. Zubaidah, M.F. Saifuddin, G.S. de Carvalho et al. BIO Web Conf [Internet] 2024;148:01003. Available at: https://www.bio-conferences.org/10.1051/bioconf/202414801003</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Irham L.M., Amukti D.P., Adikusuma W. et al. Trends in drug repurposing for chronic hepatitis-B infection: bibliometric-based approach 1990–2024. In: BIO Web of Conferences. EDP Sciences; 2025.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Prasetyaning A., Muhammad I., Surono S. et al. International developments in atherosclerosis disease research using precision medicine (1994–2024): a bibliometric analysis. Scr Med (Brno) [Internet] 2025;56(2):395–404. Available at: https://scindeks.ceon.rs/ Article.aspx?artid=2490-33292502395A</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Chen S., Ding Y. A bibliometric analysis on the risk factors of cancer. Genes, Chromosomes, Cancer 2025;64(1):e70019. DOI: 10.1002/gcc.70019</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ge Y., Chao T., Sun J. et al. Frontiers and hotspots evolution in psycho-cardiology: a bibliometric analysis from 2004 to 2022. Curr Probl Cardiol 2022;47(12):101361. DOI: 10.1016/j.cpcardiol.2022.101361</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Yeerlan J., He B., Hu X., Zhang L. Global research trends and hotspots for ferroptosis, necroptosis, and pyroptosis in Alzheimer’s disease from the past to 2023: a combined bibliometric review. J Alzheimers Dis Rep 2024;8(1):129–42. DOI: 10.3233/ADR-230092</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Zheng C., Wen X., Zhang L. et al. Research situation, hot spots, and global trends of melasma therapy: Bibliometric insights and visual analysis from 2000 to 2023. J Cosmet Dermatol 2024;23(11):3667–83. DOI: 10.1111/jocd.16438</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Yang M., Gong C., Song K. et al. APPL1 is a prognostic biomarker and correlated with Treg cell infiltration via oxygen-consuming metabolism in renal clear cell carcinoma. Oxid Med Cell Longev 2023;2023:5885203. DOI: 10.1155/2023/5885203</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Xu T., Wei D., Yang Z. et al. ApoM suppresses kidney renal clear cell carcinoma growth and metastasis via the Hippo-YAP signaling pathway. Arch Biochem Biophys 2023 Jul 15;743:109642. DOI: 10.1016/j.abb.2023.109642</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Luo J., Yi T., Wang Y. et al. ESM1 promote proliferation, invasion and angiogenesis via Akt/mTOR and Ras pathway in kidney renal clear cell carcinoma. Sci Rep 2025;15(1):4902. DOI: 10.1038/s41598-024-82400-z</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Lin L., Gong S., Deng C. et al. PTK6: An emerging biomarker for prognosis and immunotherapeutic response in clear cell renal carcinoma (KIRC). Heliyon 2024;10(7):e29001. DOI: 10.1016/j.heliyon.2024.e29001</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Li S., Wang X., Wang Q. et al. Effects and prognostic values of circadian genes CSNK1E/GNA11/KLF9/THRAP3 in kidney renal clear cell carcinoma via a comprehensive analysis. Bioengineering (Basel) 2022;9(7):306. DOI: 10.3390/bioengineering9070306</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Zhang C., Feng X., Wang C. et al. Bibliometric analysis of scientific publications in rheumatology journals from China and other top-ranking countries between 2007 and 2017. PeerJ 2019;7:e6825. DOI: 10.7717/peerj.6825</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>enbari Oskouie I., Alemi H., Khavandgar N. et al. Global research trends on colorectal cancer (2014–2023): a scientometric and visualized study. Arch Iran Med 2024;27(10):563–72. DOI: 10.34172/aim.31944</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Zheng S., Wang Y., Geng J. et al. Global trends in research on MOG antibody-associated disease: bibliometrics and visualization analysis. Front Immunol 2024;15:1278867. DOI: 10.3389/fimmu.2024.1278867</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Hashimoto H., Sekine M., Nishizaki Y et al. Global trends in the value of author order across medical publications: a cross-sectional bibliometric study. Clin Transl Sci 2025;18(2):e70157. DOI: 10.1111/cts.70157</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Nagy Á., Munkácsy G., Győrffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep 2021;11(1):6047. DOI: 10.1038/s41598-021-84787-5</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Chang S., Yim S., Park H. The cancer driver genes IDH1/2, JARID1C/KDM5C, and UTX/KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Exp Mol Med 2019 Jun 20;51(6):1–17. DOI: 10.1038/s12276-019-0230-6</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Qin C., Liu S., Zhou S. et al. PIK3C2A is a prognostic biomarker that is linked to immune infiltrates in kidney renal clear cell carcinoma. Front Immunol 2023;14:1114572. DOI: 10.3389/fimmu.2023.1114572</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Zhu H., Lu J., Zhao H. et al. Functional long noncoding RNAs (lncRNAs) in clear cell kidney carcinoma revealed by reconstruction and comprehensive analysis of the lncRNA-miRNA-mRNA regulatory network. Med Sci Monit 2018;24:8250–63. DOI: 10.12659/MSM.910773</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Wang J., Chang H., Su M. et al. Identification of HGD and GSTZ1 as biomarkers involved metabolic reprogramming in kidney renal clear cell carcinoma. Int J Mol Sci 2022;23(9):4583. DOI: 10.3390/ijms23094583</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Li X., Rokohl A.C., Ju X. et al. Global research trends in the treatment of squamous cell carcinoma over the past decade: a bibliometric analysis. Adv Ophthalmol Pract Res 2024;4(4):209–15. DOI: 10.1016/j.aopr.2024.08.001</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Yang G.H., Ma X.D., Wei X.F. et al. A Novel KIF4A-related model for predicting immunotherapy response and prognosis in kidney renal clear cell carcinoma. Comb Chem High Throughput Screen 2025;28(4):691–710. DOI: 10.2174/0113862073296897240212114403</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Sun W., Xu P., Gao K. et al. Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer. J Cell Mol Med 2024;28(8):e18309. DOI: 10.1111/jcmm.18309</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Gao Y., Hou H., Cang Q. et al. Global research trends and future directions for buckwheat as a smart crop: a bibliometric and content analysis. Foods 2024;13(24):4068. DOI: 10.3390/foods13244068</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Han M., Niu H., Duan F. et al. Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis. Front Oncol 2024;14:1383805. DOI: 10.3389/fonc.2024.1383805</mixed-citation></ref></ref-list></back></article>
